MetaCap

Trevi Therapeutics Inc. (TRVI)

NASDAQ: TRVIHealth CareBiotechnology: Pharmaceutical PreparationsUSD

13.35-0.37 (-2.70%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

TRVI stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.40
52-week range
9.82 – 20.22
Day range
13.23 – 13.90
Volume / Avg
2.09M / 2.00M
Beta
—

52-week range

$9.82$20.22

TRVI stock today

Trevi Therapeutics (TRVI) closed at $13.35 on Nov 20, down 2.70% (-$0.37), versus the S&P 500's 3.70% decline. Shares are 34.0% below their 52-week high of $20.22, set on Jul 17, 2026 and 35.9% above the 52-week low of $9.82, in the middle of the past year's range. TRVI is up 6.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 21.5%.

Trevi Therapeutics has posted a net loss over the last twelve months (EPS of -$0.40), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Trevi Therapeutics

Company profile

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Ms. Jennifer L. Good
Headquarters
New Haven, CT
Employees
34
IPO year
2019

Financial highlights

Full financials

Trevi Therapeutics reported a net loss of $42.8 million, compared with a loss of $47.9 million a year earlier. Diluted earnings per share came in at -$0.32.

Trevi Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-42.76M$-47.91M$-29.07M$-29.15M$-33.94M
EPS (diluted)$-0.32$-0.47$-0.29$-0.45$-1.49

Analyst forecast

Forecast

Consensus (11 analysts)

strong_buy

Avg. price target

$28.18+111.09%

  • Strong buy 2
  • Buy 9
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $23.00High $40.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.13 vs $-0.13

TRVI news

All TRVI news

Trevi Therapeutics peers

Health Care sector
TRVI peer companies
CompanyPrice% ChgMarket capCompare
HRMYHarmony Biosciences Holdings Inc.32.59-1.18%$1.91Bvs TRVI
BHVNBiohaven Ltd.12.39-9.23%$1.87Bvs TRVI
IMNMImmunome Inc.15.69-5.54%$1.85Bvs TRVI
VERAVera Therapeutics Inc. Class A25.45-4.86%$1.84Bvs TRVI
AUPHAurinia Pharmaceuticals Inc14.70-1.28%$1.97Bvs TRVI
SEPNSepterna Inc.38.61-1.51%$1.84Bvs TRVI
MRVIMaravai LifeSciences Holdings Inc. Class A6.98-2.92%$1.81Bvs TRVI
ZYMEZymeworks Inc.26.14-2.68%$1.81Bvs TRVI

Indexes, lists and sector

Trevi Therapeutics stock FAQ

What is Trevi Therapeutics's stock price today?

TRVI last traded at $13.35 as of Nov 20, 4:00 PM EST, down 2.70% on the day. Prices are delayed at least 15 minutes.

Who is Trevi Therapeutics's CEO?

Ms. Jennifer L. Good is the chief executive officer of Trevi Therapeutics Inc., which has about 34 employees.

What is the TRVI 52-week high?

The 52-week high for TRVI is $20.22 and the 52-week low is $9.82. The stock is currently 34.0% below its high.

Compare TRVI